Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the fourth quarter and full year 2024 financial and business results on Tuesday, February 25, 2025 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at https://www.supernus.com/Investors.

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company’s Investor Relations website at www.supernus.com/Investors. The webcast will be available on the Company’s website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.

For more information, please visit www.supernus.com/.

CONTACTS:

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591

or

INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com

Staff

Recent Posts

IDC Report: Huawei Ranks No.1 in Global Wrist-Worn Market in Q1

Huawei wearable devices Surpassed 200 Million Cumulative Shipments SHENZHEN, China, June 14, 2025 /PRNewswire/ -- According to…

9 hours ago

Decisely Notifies Individuals of Data Security Incident

ALPHARETTA, Ga., June 13, 2025 /PRNewswire/ -- Decisely learned of a data security incident that may…

21 hours ago

Abstractive Health Launches Clinical Time Machine, the First AI Game Built on Real Historical Patient Records

NEW YORK--(BUSINESS WIRE)--#digitalhealth--Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians…

1 day ago

The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare

Veteran Leader Brings Deep Industry Expertise to Advance Berwyn's Healthcare Strategy INDEPENDENCE, Ohio, June 13,…

1 day ago

Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®

BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture…

1 day ago

Skypoint Launches Lia and Scribe: AI-Powered Agents Redefining Clinical Workflow Efficiency and Social Determinants of Health (SDOH) Data Capture

PORTLAND, Ore., June 13, 2025 /PRNewswire/ -- Skypoint, a leading provider of HITRUST r2-certified AI platform…

1 day ago